Natural Molecular Testing

As part of the settlement reached with the agency, NMT will also cease all operations, end its plans to reorganize, and liquidate its assets. 

GenMark Diagnostics CEO Hany Massarany elaborated recently on the company's plans for its automated NexGen system and its associated test menu, as well as GenMark's efforts to reach European customers.

Luminex hit a number of "unexpected speed bumps" in the third quarter that caused the company to miss both its internal and Wall Street's projections, and to lower its 2013 revenue guidance.

Natural Molecular Testing created a stir in the marketplace last week when it announced it would be converting its pharmacogenetic test services to a new panel based on Luminex's xMAP multiplex bead array technology.

NEW YORK (GenomeWeb News) – GenMark Diagnostics said after the close of the market Monday that it has lowered its annual revenue guidance to approximately $30 million from its previous expectation of $35 million.

NEW YORK (GenomeWeb News) – While GenMark Diagnostics continues to seek clarification around the consequences of Luminex's collaboration and licensing deal wit

The story has been updated to include comments from GenMark.

NEW YORK (GenomeWeb News) – Luminex and Natural Molecular Testing have entered into a multiyear collaboration and licensing deal, resulting in a comprehensive personalized medicine panel.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.